Medpace Holdings, Inc. ranks in an above-average position in its peer group, with stability as the least supportive dimension. The market setup has weakened, with clear trend damage and relative performance under pressure.
Peer-relative scores, weakest to strongest
Medpace Holdings provides clinical research services to support drug development. The company operates as a contract research organization (CRO) for the pharmaceutical industry.
MEDP is priced as a cyclical CRO beneficiary, not a quality anchor. Despite a sector-leading operating margin of 24.7%, the market focuses on short-term order swings and interprets every cancellation wave as a sign of cyclical risk, which means even temporary project declines can trigger sharp price reactions. MEDP combines high margins with rapid AI adoption in the CRO sector, but the market penalizes any uncertainty in its project-driven revenues with outsized volatility—1Y volatility stands at 41.5%, well above most peers. The valuation fluctuates more than fundamentals would suggest, and another uptick in project cancellations could trigger an immediate hard rerating.
Break down MEDP's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.